source
- Crossover fundraisings may hit $4.2 billion in 2026, with 2025 rounds still leading historic totalsCrossover rounds are viewed as a bridge to public markets, with Jim Healy of Sofinnova Investments saying a large raise signals a company has reached a level of maturity and broader institutional i…
- BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…